FDA’s Draft Guidance on Externally Controlled Trials Answers Some Questions, Leaves Others Unanswered
FDA Law Blog
APRIL 23, 2023
The Draft Guidance recommends that, where possible, the outcome should be assessed by individuals blinded to treatment status, which may require re-adjudication of externally controlled data. This is potentially discouraging to sponsors of drugs intended for rare and serious diseases.
Let's personalize your content